keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer vaccine

keyword
https://www.readbyqxmd.com/read/29907693/exosomes-shuttle-trex1-sensitive-ifn-stimulatory-dsdna-from-irradiated-cancer-cells-to-dendritic-cells
#1
Julie M Diamond, Claire Vanpouille-Box, Sheila Spada, Nils-Petter Rudqvist, Jessica Chapman, Beatrix Ueberheide, Karsten A Pilones, Yasmeen Sarfraz, Silvia C Formenti, Sandra Demaria
Radiotherapy (RT) used at immunogenic doses leads to accumulation of cytosolic double-stranded DNA (dsDNA) in cancer cells, which activates type I IFN (IFN-I) via the cGAS/STING pathway. Cancer cell-derived IFN-I is required to recruit BATF3-dependent dendritic cells (DCs) to poorly immunogenic tumors and trigger antitumor T-cell responses in combination with immune checkpoint blockade. We have previously demonstrated that the exonuclease TREX1 regulates radiation immunogenicity by degrading cytosolic dsDNA...
June 15, 2018: Cancer Immunology Research
https://www.readbyqxmd.com/read/29899661/breast-cancer-immunotherapy-an-update
#2
REVIEW
Issam Makhoul, Mohammad Atiq, Ahmed Alwbari, Thomas Kieber-Emmons
The immune system plays a major role in cancer surveillance. Harnessing its power to treat many cancers is now a reality that has led to cures in hopeless situations where no other solutions were available from traditional anticancer drugs. These spectacular achievements rekindled the oncology community's interest in extending the benefits to all cancers including breast cancer. The first section of this article reviews the biological foundations of the immune response to different subtypes of breast cancer and the ways cancer may overcome the immune attack leading to cancer disease...
2018: Breast Cancer: Basic and Clinical Research
https://www.readbyqxmd.com/read/29881518/immunotherapy-in-breast-cancer-the-new-frontier
#3
REVIEW
Zishuo I Hu, Heather L McArthur
Purpose of review: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. Recent findings: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. Summary: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes...
2018: Current Breast Cancer Reports
https://www.readbyqxmd.com/read/29874101/her2-based-immunotherapy-for-breast-cancer
#4
Naipeng Cui, Jianhong Shi, Chuanwei Yang
Resistance to therapies and disease recurrences after surgery or treatment are common challenges in breast cancer management in clinic. Active immunotherapy using human epidermal growth factor receptor 2 (HER2)-targeted vaccines represents an attractive option in combating breast cancer. Different HER2-derived vaccines have been developed over the years. Many clinical trials have been carried out in evaluating HER2-based vaccines. The authors reviewed current literature on HER2-based vaccines in clinical trials...
June 6, 2018: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29869958/use-of-breast-cancer-screening-and-its-association-with-later-use-of-preventive-services-among-medicare-beneficiaries
#5
Stella K Kang, Miao Jiang, Richard Duszak, Samantha L Heller, Danny R Hughes, Linda Moy
Purpose To retrospectively assess whether there is an association between screening mammography and the use of a variety of preventive services in women who are enrolled in Medicare. Materials and Methods U.S. Medicare claims from 2010 to 2014 Research Identifiable Files were reviewed to retrospectively identify a group of women who underwent screening mammography and a control group without screening mammography in 2012. The screened group was divided into positive versus negative results at screening, and the positive subgroup was divided into false-positive and true-positive findings...
June 5, 2018: Radiology
https://www.readbyqxmd.com/read/29860986/immunotherapy-and-prevention-of-pancreatic-cancer
#6
REVIEW
Alexander H Morrison, Katelyn T Byrne, Robert H Vonderheide
Pancreatic cancer is the third-leading cause of cancer mortality in the USA, recently surpassing breast cancer. A key component of pancreatic cancer's lethality is its acquired immune privilege, which is driven by an immunosuppressive microenvironment, poor T cell infiltration, and a low mutational burden. Although immunotherapies such as checkpoint blockade or engineered T cells have yet to demonstrate efficacy, a growing body of evidence suggests that orthogonal combinations of these and other strategies could unlock immunotherapy in pancreatic cancer...
June 2018: Trends in Cancer
https://www.readbyqxmd.com/read/29848327/immunotherapeutic-interventions-of-triple-negative-breast-cancer
#7
REVIEW
Zehuan Li, Yiran Qiu, Weiqi Lu, Ying Jiang, Jin Wang
Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast cancer that lacks the expression of oestrogen receptors, progesterone receptors and human epidermal growth factor receptor 2. Although TNBC is sensitive to chemotherapy, the overall outcomes of TNBC are worse than for other breast cancers, and TNBC is still one of the most fatal diseases for women. With the discovery of antigens specifically expressed in TNBC cells and the developing technology of monoclonal antibodies, chimeric antigen receptors and cancer vaccines, immunotherapy is emerging as a novel promising option for TNBC...
May 30, 2018: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29843073/breast-and-cervical-cancer-incidence-and-mortality-trends-in-russia-1980-2013
#8
Anton Barchuk, Alexander Bespalov, Heini Huhtala, Tuvshinjargal Chimed, Irina Laricheva, Alexey Belyaev, Freddie Bray, Ahti Anttila, Anssi Auvinen
BACKGROUND: Breast and cervical cancer are among the leading causes of preventable cancer deaths in women in Russia. The aim of this study is to analyze changes in breast and cervical cancer incidence and mortality trends using data from the Russian State Cancer Registry. METHODS: The age-standardized rates of cervical cancer incidence (1993-2013) and mortality (1980-2013) were analyzed using piecewise linear regression. Age-period-cohort models were used to estimate the temporal effects and provide future predictions...
May 26, 2018: Cancer Epidemiology
https://www.readbyqxmd.com/read/29773491/association-between-number-of-preventive-care-guidelines-and-preventive-care-utilization-by-patients
#9
Glen B Taksler, Elizabeth R Pfoh, Kurt C Stange, Michael B Rothberg
INTRODUCTION: The number of preventive care guidelines is rapidly increasing. It is unknown whether the number of guideline-recommended preventive services is associated with utilization. METHODS: The authors used Poisson regression of 390,778 person-years of electronic medical records data from 2008 to 2015, in 80,773 individuals aged 50-75 years. Analyses considered eligibility for 11 preventive services most closely associated with guidelines: tobacco cessation; control of obesity, hypertension, lipids, or blood glucose; influenza vaccination; and screening for breast, cervical, or colorectal cancers, abdominal aortic aneurysm, or osteoporosis...
May 8, 2018: American Journal of Preventive Medicine
https://www.readbyqxmd.com/read/29758415/anti-tumor-effects-of-propranolol-adjuvant-activity-on-a-transplanted-murine-breast-cancer-model
#10
Somayeh Ashrafi, Reza Shapouri, Ahmad Shirkhani, Mehdi Mahdavi
Propranolol (Pro), a non-specific β-adrenergic blocking drug, competitively prevents the binding of catecholamines to receptors and suppresses cancer cells. The anti-tumor activity of propranolol has been proved in different kinds of cancers. In this study, we assessed the adjuvant activity of propranolol combined with a tumor vaccine model on the immunological parameters of breast tumor-bearing mice. Breast tumor pieces were implanted into the flank of inbred BALB/C female mice from stock mice. Tumor-bearing mice were treated with tumor antigen lysate vaccine and propranolol/Vaccine (Pro/Vac) combination (as treatment groups), propranolol and PBS (as control groups) for 5 consecutive days, every 12 h...
May 11, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29755647/autologous-tumor-cells-bacillus-calmette-gu%C3%A3-rin-formalin-based-novel-breast-cancer-vaccine-induces-an-immune-antitumor-response
#11
María José Godoy-Calderón, Víctor Salazar, Eglys González-Marcano, Ana Federica Convit
Autologous cancer cell vaccines represent a multivalent patient-specific treatment. Studies have demonstrated that these immunotherapies should be combined with immunomodulators to improve results. We tested in breast cancer the antitumor effects of a 200 µg autologous tumor cells homogenate combined with 0.0625 mg of bacillus Calmette-Guérin (BCG), and 0.02% formalin. We used a 4T1 murine model of BALB/c receiving four weekly injections of either this vaccine or control treatments. The control treatments were either Phosphate Buffer Saline, BCG treated with formalin, or the tumor cells homogenate plus BCG alone...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29753042/application-of-e75-peptide-vaccine-in-breast-cancer-patients-a-systematic-review-and-meta-analysis
#12
REVIEW
Reyhane Chamani, Peyman Ranji, Maryam Hadji, Azin Nahvijou, Ebrahim Esmati, Ali Mohammad Alizadeh
The E75 peptide vaccine, derived from tumor-associated antigen HER2, is the most frequently studied anti-HER2 vaccination strategy for the treatment of breast cancer patients. It has been investigated in the several phases Ι/Π of the clinical trials and is currently being evaluated in a randomized multicenter phase III clinical trial. We conducted a systematic review and meta-analysis to clarify the outcomes of the E75 peptide vaccine including the therapeutic efficacy, the disease recurrence, the survival rate, and the side effects...
May 9, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29732989/towards-breast-cancer-vaccines-progress-and-challenges
#13
Javad Behravan, Atefeh Razazan, Ghazal Behravan
Breast cancer is the second leading cause of cancer death among women. National cancer institute of the US estimates that one in eight women will be diagnosed with breast cancer during their life time. Considering the devastating effects of the disease and the alarming numbers many scientists and research groups have devoted their research to fight breast cancer. Several recommendations are to be considered as preventing measures which include living a healthy life style, regular physical activity, weight control and, smoking cessation...
May 2, 2018: Current Drug Discovery Technologies
https://www.readbyqxmd.com/read/29731862/synergistic-anti-tumor-effects-of-dasatinib-and-dendritic-cell-vaccine-on-metastatic-breast-cancer-in-a-mouse-model
#14
Ningning Song, Hulin Guo, Jia Ren, Suhong Hao, Xinchao Wang
Immunotherapy is currently considered as one of the major anti-tumor modalities, but its efficacy is limited. Dasatinib could improve the expansion and recruitment of cluster of differentiation (CD) 8+ T cells and natural killer (NK) cells to the tumor microenvironment. The present study aimed to evaluate the synergistic anti-tumor effects of dasatinib with dendritic cell (DC) vaccine in metastatic breast cancer. Dasatinib with DC vaccine was administered to mice inoculated with 4T1 breast cancer cells. Thereafter, tumor volume was measured every other day...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29721396/m7824-a-novel-bifunctional-anti-pd-l1-tgf%C3%AE-trap-fusion-protein-promotes-anti-tumor-efficacy-as-monotherapy-and-in-combination-with-vaccine
#15
Karin M Knudson, Kristin C Hicks, Xiaoling Luo, Jin-Qiu Chen, Jeffrey Schlom, Sofia R Gameiro
Tumors evade host immune surveillance through multiple mechanisms, including the generation of a tumor microenvironment that suppresses immune effector function. Secretion of TGFβ and upregulation of immune checkpoint programmed cell death ligand-1 (PD-L1) are two main contributors to immune evasion and tumor progression. Here, we examined the efficacy of a first-in-class bifunctional checkpoint inhibitor, the fusion protein M7824, comprising the extracellular domain of human TGFβRII (TGFβ Trap) linked to the C-terminus of human anti-PD-L1 heavy chain (αPD-L1)...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29704370/evaluation-of-healthy-fit-a-community-health-worker-model-to-address-hispanic-health-disparities
#16
Louis D Brown, Denise Vasquez, Jennifer J Salinas, Xiaohui Tang, Hector Balcázar
INTRODUCTION: Hispanics in the United States have disproportionately high rates of obesity, hypertension, and diabetes and poorer access to preventive health services. Healthy Fit uses community health workers to extend public health department infrastructure and address Hispanic health disparities related to cardiovascular disease and access to preventive health services. We evaluated the effectiveness of Healthy Fit in 1) reaching Hispanic Americans facing health disparities, and 2) helping participants access preventive health services and make behavior changes to improve heart health...
April 26, 2018: Preventing Chronic Disease
https://www.readbyqxmd.com/read/29693245/developing-anti-her2-vaccines-breast-cancer-experience
#17
REVIEW
Aydah Al-Awadhi, James Lee Murray, Nuhad K Ibrahim
Breast cancer accounts for more than one million new cases annually and is the leading cause of death in women globally. HER2 overexpression induces cellular and humoral immune responses against the HER2 protein and is associated with higher tumour proliferation rates. Trastuzumab-based therapies are effectively and widely used as standard of care in HER2-amplified/overexpressed breast cancer patients; one cited mechanism of action is the induction of passive immunity and antibody-dependent cellular cytotoxicity against malignant breast cancer cells...
April 25, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29681616/progress-in-preventive-therapy-for-cancer-a-reminiscence-and-personal-viewpoint
#18
REVIEW
Jack Cuzick
Prophylactic drug treatment with aspirin, statins and anti-hypertensive agents has had a major impact on the incidence of cardiovascular disease and is now well established. Progress in therapeutic cancer prevention has been much slower; only recently have effective agents been clearly established. Breast cancer has led the way and endocrine agents used to treat it-notably tamoxifen and the aromatase inhibitors-have now been shown to have a substantial preventive effect as well. However, these agents carry some toxicity and thus identifying high-risk women who are likely to benefit most is a key priority...
May 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29675979/senescent-cells-re-engineered-to-express-soluble-programmed-death-receptor-1-for-inhibiting-programmed-death-receptor-1-programmed-death-ligand-1-as-a-vaccination-approach-against-breast-cancer
#19
Zehong Chen, Kang Hu, Lieting Feng, Ruxiong Su, Nan Lai, Zike Yang, Shijun Kang
Various types of vaccines have been proposed as approaches for prevention or delay of the onset of cancer by boosting the endogenous immune system. We previously developed a senescent-cell-based vaccine, induced by radiation and veliparib, as a preventive and therapeutic tool against triple-negative breast cancer. However, the programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) pathway was found to play an important role in vaccine failure. Hence, we further developed soluble programmed death receptor-1 (sPD1)-expressing senescent cells to overcome PD-L1/PD-1-mediated immune suppression while vaccinating to promote dendritic cell (DC) maturity, thereby amplifying T-cell activation...
June 2018: Cancer Science
https://www.readbyqxmd.com/read/29657904/immunotherapy-for-breast-cancer-current-and-future-strategies
#20
Austin D Williams, Kyle K Payne, Avery D Posey, Christine Hill, Jose Conejo-Garcia, Carl H June, Julia Tchou
Purpose of Review: The breast tumor microenvironment is immunosuppressive and is increasingly recognized to play a significant role in tumorigenesis. A deeper understanding of normal and aberrant interactions between malignant and immune cells has allowed researchers to harness the immune system with novel immunotherapy strategies, many of which have shown promise in breast cancer. This review discusses the application of immunotherapy to the treatment of breast cancer. Recent Findings: Both basic science and clinical trial data are rapidly developing in the use of immunotherapy for breast cancer...
December 2017: Current Surgery Reports
keyword
keyword
43344
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"